Drug Trial Radar · NCT05387603
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Last checked: Nov 20, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 1, 2022
Primary completion
Oct 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Lund University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
Conditions
- Neuroendocrine Tumors
Interventions
177Lu-DOTATOCDrug
The investigational medicinal product (IMP) is 177Lu-DOTATOC which is registered as an orphan drug by the EMA ( European Medicines Agency) for the treatment of GEP-NEN (gastro-entero-pancreatic neuroendocrine tumor). The IMP will be administered to participants both in the control arm and the experimental arms, but with different intervals, but the same activity; 7.5 Gbq per dosing.
CapecitabineDrug
Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median progression free survival (PFS) defined as time from randomization to radiological progression.Time frame: Before start of treatment (within 4 weeks), then every 10 +/- 2 weeks weeks, at follow up (every 3-6 month (investigators choice) until progression.
- Median progression free survival (PFS) defined as time from randomization to radiological progression.Time frame: Before start of treatment (within 4 weeks), then every 10 +/- week at follow up (every 3-6 month (investigators choice) until death.
- Median progression free survival (PFS) defined as time from randomization to radiological progression,Time frame: Before start of treatment (within 4 weeks), then every 10 +/- 2 weeks, at follow up (every 3-6 month (investigators choice) or patients withdrawal of concent.. No end can be given.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Sahlgrenska University Hospital, Dept. of Oncology
Gothenburg, Sweden · Recruiting
Skåne University Hospital, Dept. of Oncology
Lund, Sweden · Recruiting
Karolinska University Hospital, Dept. of Oncology
Stockholm, Sweden · Recruiting
Accademical Hospital, Uppsala, Dept. of Oncology
Uppsala, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.